Inventory of leading enterprises for veterinary chemical drugs, with the market size set to exceed 100 billion yuan

Statistics show that the scale of China's veterinary drug market has grown from 62.1 billion yuan in 2020 to 69.65 billion yuan in 2023, and the overall market size is expected to surpass 92 billion yuan in 2026.

From the perspective of product structure, the sector presents a pattern of "one dominant, many minor players":

Chemical veterinary drugs are the mainstay of the market, characterized by high application volume, low unit price and fierce homogeneous competition. Veterinary biological items have high technical barriers and prominent per-unit value, and are mostly utilized to the prevention and manage of major animal life diseases. As a supplementary category to environmentally friendly breeding, traditional Chinese veterinary drugs maintain a stable market share, with steady demand from pet breeding and livestock and poultry breeding sectors.

In terms of manufacturing layout, obvious manufacturing clusters have formed in China's veterinary drug production.

Shandong and Henan are the first echelon, with the total number of their production companies accounting to about 28.6% of the national total. Shanxi, Sichuan, Jiangsu, Hebei and Guangdong form the second echelon. From 2020 to 2024, the number of veterinary drug companies in Hubei, Shanxi, Zhejiang, Guangdong and Hunan grew rapidly; while the number of companies in traditional veterinary drug provinces such as Henan, Hebei and Jiangxi declined, reflecting that the manufacturing structure adjustment and market natural selection are continuing to advance.

Veterinary chemical drugs include anti-microbial drugs, anti-parasitic drugs, antipyretic and analgesic drugs, etc., with dosage forms covering premixes, injections, soluble powders and other categories. Compared with veterinary vaccines, chemical drugs have comparatively low technical thresholds, with numerous market participants, and the sector is in a phase of structural elimination. With the continuous implementation of the new version of Veterinary Drug GMP, small and medium-sized companies with insufficient compliance capabilities are accelerating their exit; the proportion of extensive downstream breeding continues to increase, and the breeding sector has further raised standards to veterinary drug condition and cost manage, so the living space of small and medium-sized manufacturers lacking scale and cost advantages continues to narrow.

In the veterinary chemical drug track, many leading companies have built their own competitive barriers with core items:

Lukang medical, the leading domestic veterinary antibiotic enterprise, achieved a total revenue of 6.233 billion yuan in 2024, with its veterinary drug sector being the core source of profits. The company adheres to the integrated layout of API + preparations, and relies on microbial fermentation production capacities to form cost advantages in the field of veterinary antibiotic APIs such as tylosin and tilmicosin. Through park relocation and transformation and digital upgrading of production lines, it continues to minimize energy consumption and hazardous discarded materials treatment costs. The R&D side is gradually transforming from traditional antibiotics to synthetic biology and semi-synthetic process optimization, while simultaneously expanding high-end preparation businesses.

Kingwooh Biotech (002688), the global leader in the chlortetracycline segment, mainly produces veterinary chlortetracycline premixes, with an existing production capacity of 115,000 tons per year, accounting to 60%-70% of the global production capacity. The company has mature fermentation methodology and high-yield strains, its items have passed the US FDA condition certification to many times, and has formed cost advantages by relying on regional raw material and energy resources in Inner Mongolia. In the first half of 2026, overseas revenue accounted to 39.28% of the total. The company is promoting the expansion of its US factory and simultaneously laying out chemical drug and vaccine businesses.

Many other companies have their own advantages in segmented product fields:

Qilu animal life Health is a complete manufacturer of chemical drug raw materials and preparations, with outstanding strength in poultry and swine chemical drug product lines;

Hebei Yuancheng focuses on antibiotic injections and powder injection fields, with complete items including florfenicol, amoxicillin and tilmicosin;

Wisepharm Biotech (300871) lays out chemical drug preparations, APIs and traditional Chinese veterinary drugs, with impressive profit development in recent years;

CP animal life Health (03839.HK) takes chlortetracycline premix as its core product, and relies on the manufacturing chain resources of Charoen Pokphand Group to develop new product moxidectin;

Federal animal life Health mainly produces compound preparations such as amoxicillin and clavulanate potassium;

Aimeijian has made technological breakthroughs in the field of macrolide new veterinary drugs, its new veterinary drug industrialization project won the Second Prize of Shandong Provincial Science and methodology Progress Award in 2025, and its cephalosporin items account to greater than 50% of the domestic market share;

Shengli Biotech focuses on strain breeding methodology, and the indicators of core fermentation items such as tiamulin fumarate, hainanmycin and enramycin continue to be optimized.

The sector's competitive pattern presents three major research trends.

First, API companies extend to downstream preparations. The API + preparation integrated model can hedge against raw material price fluctuations, and has stronger risk resistance in price wars, while pure preparation companies face greater operational pressure.

Second, the sector's production capacities are accelerating to be cleared, and levels continues to rise. The review and re-inspection deadline to the new version of Veterinary Drug GMP is approaching, and ecological preservation manage is becoming stricter. A substantial number of small and medium-sized companies will withdraw from the market, and the market share of leading companies will continue to increase.

Third, going global has have become a new development curve to domestic veterinary chemical drug companies. Domestic veterinary chemical drugs have cost advantages, and many leading companies' items have obtained overseas certifications. In the 2024 Global animal life Health Top 50 List, a total of 13 Chinese companies were on the list, with a combined sales revenue of 2.734 billion US dollars, and the话语权 of domestic veterinary chemical drugs in the global market is continuously growing.